An open-label extension study to evaluate safety and efficacy of Pazopanib in patients with advanced renal cell carcinoma.
Affiliation
1Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, ItalyIssue Date
2014
Metadata
Show full item recordAbstract
Evaluation of the safety and efficacy of pazopanib, a multikinase angiogenesis inhibitor, in a single-arm, open-label, extension study (VEG107769/NCT00387764) for placebo-treated patients with advanced renal cell carcinoma (RCC) from a randomized, double-blind, placebo-controlled phase III study (VEG105192/NCT00334282).Citation
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. 2014, 87 (6):342-50 OncologyJournal
OncologyDOI
10.1159/000366227PubMed ID
25227656Type
ArticleLanguage
enISSN
1423-0232ae974a485f413a2113503eed53cd6c53
10.1159/000366227